Last checked at 
* Vaccine 94.1% effective based on full trial results
* Efficacy rate consistent across age, race and ethnicity
* Moderna shares hit new record high above $150
* FACTBOX-Moderna's mRNA coronavirus vaccine:
(Updates Moderna shares)
By Julie Steenhuysen and Michael Erman
Nov 30 (Reuters) - Moderna Inc will apply for U.S.
and European emergency authorization for its COVID-19 vaccine on
Monday after full results from a late-stage study showed it was
94.1% effective with no serious safety concerns, the company
said.
Moderna also reported that its vaccine's efficacy rate was
consistent across age, race, ethnicity and gender demographics
as well as having a 100% success rate in preventing severe cases
of a disease that has killed nearly 1.5 million people.
The filing sets Moderna's product up to be the second
vaccine likely to receive U.S. emergency use authorization this
year following a shot developed by Pfizer and BioNTech
which had a 95% efficacy rate.
"We believe that we have a vaccine that is very highly
efficacious. We now have the data to prove it," Moderna Chief
Medical Officer Tal Zaks said. "We expect to be playing a major
part in turning around this pandemic."
Of the 196 people who contracted COVID-19 out of over 30,000
volunteers, 185 had received a placebo and 11 got the vaccine.
Moderna reported 30 severe cases, all in the placebo group,
which means the vaccine was 100% effective against severe cases.
Moderna shares opened 13% higher at a record $144 following
the results and then went on to hit a peak of $150.14, or a gain
of 668% so far this year.
"As the numbers of cases reported grows, confidence grows
that this amazing protection will be maintained in a product
that can be rolled out to protect the public," said Alexander
Edwards, associate professor in biomedical technology at
Britain's University of Reading.
In addition to filing its U.S. application, Moderna said it
would seek conditional approval from the European Medicines
Agency, which is already reviewing its data, and would continue
to talk with other regulators doing similar rolling reviews.
"Although we await the full details of these results in
published form, we can now assume that this vaccine will be
approved for use in December," said Gillies O'Bryan-Tear, chair
of policy and communications at Britain's Faculty of
Pharmaceutical Medicine.
He expected Britain's Medicines and Healthcare products
Regulatory Agency to approve the vaccine within two weeks.
Pfizer has already applied for emergency use authorization
in the United States and Europe, putting it about a week ahead
of Moderna.
'JUST OVERWHELMING'
Moderna said it was on track to have about 20 million doses
of its vaccine ready to ship in the United States by the end of
2020, enough to inoculate 10 million people.
Switzerland's Lonza, which has a contract with
Moderna to supply ingredients for the vaccine, rose 4.4%.
The vaccines developed by both Moderna and Pfizer/BioNTech
use a new technology called synthetic messenger RNA (mRNA)
whereas others, such as Britain's AstraZeneca, are using
more traditional methods.
AstraZeneca has announced an average efficacy rate of 70%
for its shot and as much as 90% for a subgroup of trial
participants who got a half dose, followed by a full dose. But
some scientists have expressed doubts about the robustness of
the 90% efficacy figure for the smaller group.
Moderna's latest efficacy result is slightly lower than an
interim analysis released on Nov. 16 of 94.5% effectiveness, a
difference that Zaks said was not statistically significant.
"At this level of effectiveness, when you just do the math
of what it means for the pandemic that's raging around us, it's
just overwhelming," said Zaks, who said he cried when he saw the
final results over the weekend.
Both the Moderna and Pfizer vaccines proved more effective
than anticipated and were far superior to the 50% benchmark set
by the U.S. Food and Drug Administration (FDA).
The past few weeks of positive vaccine results have ignited
hopes for an end to a pandemic that has battered economies and
come as new infections and COVID-19 hospitalizations are at
record levels across the United States.
Independent advisers to the FDA are scheduled to meet on
Dec. 10 to review Pfizer's data and make a recommendation to the
U.S. regulator. They will review Moderna's data a week later.
Soon after getting the green light, Moderna expects its
vaccine to be shipped to distribution points across the United
States by the government's Operation Warp Speed program and drug
distributor McKesson Corp.
The distribution is expected to be easier than Pfizer's
because while it needs to be stored in a freezer, it does not
require the ultra-cold temperature needed by Pfizer's vaccine.
CONSISTENT ACROSS AGE AND ETHNICITY
Moderna said the 196 COVID-19 cases in its trial included 33
adults over 65 years old and 42 volunteers from racially diverse
groups, including 29 Latinos, 6 Blacks, 4 Asian Americans and 3
multiracial participants. There was one death related to
COVID-19 in the placebo group during the trial.
"This is as black and white as an effect on a population
will be. Your chances of actually being sick if you've been
vaccinated are decreased 20-fold," said Moderna's Zaks.
Azra Ghani, chair in infectious disease epidemiology at
Imperial College London, said Monday's details confirmed the
vaccine was highly effective, including against severe cases.
"Whilst this does not exclude some risk of severe disease
after vaccination given the relatively small number of severe
cases, these results suggest very high efficacy," she said.
Moderna reported no new side effects since its interim
analysis, which showed the most common side effects were
fatigue, injection site redness and pain, headache and body
aches, which rose after the second dose and were short-lived.
Zaks said the vaccine caused significant flu-like symptoms
in some participants which, "goes hand-in-hand with having such
a potent vaccine." But it has not caused any significant safety
concerns so far, he said.
Moderna plans to start a new trial to test the vaccine in
adolescents before the end of the year, followed by another in
even younger volunteers early in 2021. It hopes to have the
vaccine available for adolescents by September, Zaks said.
Other vaccine makers have said they are studying their
vaccines in young people as well.
(Reporting by Julie Steenhuysen and Michael Erman; Additional
reporting by Ankur Banerjee and Manas Mishra in Bengaluru and
Kate Kelland in London; Editing by Bill Berkrot, Edwina Gibbs
and David Clarke)
